Characterization of a hERG screen using the IonWorks HT: Comparison to a hERG rubidium efflux screen

Assay and Drug Development Technologies

Volumn 3, Issue 1, 2005, Pages 47-57

  Sorota, Steve ^a   Zhang, Xue Song ^a   Margulis, Michael ^a   Tucker, Kristal ^a   Priestley, Tony ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; DOFETILIDE; NEFAZODONE; PIMOZIDE; POTASSIUM CHANNEL HERG; QUINIDINE; RUBIDIUM; TERFENADINE; VERAPAMIL;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PATCH CLAMP; PREDICTION; VOLTAGE CLAMP;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; ION CHANNEL GATING; KIDNEY; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; REPRODUCIBILITY OF RESULTS; ROBOTICS; RUBIDIUM; SENSITIVITY AND SPECIFICITY;

EID: 17344373426     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2005.3.47     Document Type: Article

References (27)

1. Kr potassium channel. Cell 1995;81:299-307.
2. Kr channel. J Gen Physiol 1996;107:611-619.
3. Smith PL, Baukrowitz T, Yellen G: The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996;379:833-836.
4. Tseng GN: I(Kr): The hERG channel. J Mol Cell Cardiol 2001;33:835-849.
5. + channels: friend and foe. Trends Pharmacol Sci 2001;22:240-246.
6. Curran ME, Splawsli I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
7. Ackerman MJ: The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc 1998;73:250-269.
8. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM: Congenital and acquired long QT syndrome. Eur Heart J 2000;21:1232-1237.
9. Mitcheson J, Chen J, Lin M, Culberson C, Sanguinetti M: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000;97:12329-12333.
10. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC: Physicochemical features of the hERG channel drug binding site. J Biol Chem 2004;279:10120-10127.
11. Perry M, De Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson JS: Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 2004;66:240-249.
12. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76:110-119.
13. Rampe D, Roy ML, Dennis A, Brown AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417:28-32.
14. Rampe D, Murawsky MK, Grau J, Lewis EW, The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788-793.
15. Bischoff U, Schmidt C, Netzer R, Pongs O: Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000; 406:341-343.
16. Zhou Z, Vorperian VR, Gong Q, Zhang S, January CT: Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999;10:836-843.
17. Walker BD, Valenzuela SM, Singleton CB, Tie H, Bursill JA, Wyse KR, Qiu MR, Breit SN, Campbell TJ: Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate. Br J Pharmacol 1999;127:243-251.
18. Anumonwo JM, Horta J, Delmar M, Taffet SM, Jalife J: Proton and zinc effects on HERG currents. Biophys J 1999;77:282-298.
19. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001;430:147-148.
20. Netzer R, Bischoff U, Ebneth A: HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Dev 2003;6:462-469.
21. Cheng CS, Alderman D, Kwash J, Dessaint J, Patel R, Lescoe MK, Kinrade MB, Yu W: A high-throughput HERG potassium channel function assay: An old assay with a new look. Drug Dev Ind Pharm 2002;28:177-191.
22. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, Schroeder K: High throughput ion-channel pharmacology: Planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1:127-135.
23. Yang T, Snyders D, Roden DM: Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-744.
24. Kang J, Wang L, Cai F, Rampe D: High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol 2000;392:137-140.
25. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998;54:695-703.
26. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93: 407-411.
27. + efflux assay. J Biomol Screen 2004;9: 588-597.